Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 23 of 23 entries
Sorted by: Best Match Show Resources per page
Hypertrophic Cardiomyopathy.

Current treatment options in cardiovascular medicine

Behr ER, McKenna WJ.
PMID: 12408787
Curr Treat Options Cardiovasc Med. 2002 Dec;4(6):443-453. doi: 10.1007/s11936-002-0039-8.

When an individual is diagnosed with hypertrophic cardiomyopathy (HCM), all relatives potentially affected by Mendelian autosomal-dominant inheritance should be evaluated with an electrocardiogram (ECG) and echocardiogram. Genetic testing should be considered in high-risk mutations where there are diagnostic uncertainties....

Cite
Behr ER, McKenna WJ. Hypertrophic Cardiomyopathy. Curr Treat Options Cardiovasc Med. 2002;4(6):443-453doi: 10.1007/s11936-002-0039-8.
Behr, E. R., & McKenna, W. J. (2002). Hypertrophic Cardiomyopathy. Current treatment options in cardiovascular medicine, 4(6), 443-453. https://doi.org/10.1007/s11936-002-0039-8
Behr, Elijah R., and McKenna, William J.. "Hypertrophic Cardiomyopathy." Current treatment options in cardiovascular medicine vol. 4,6 (2002): 443-453. doi: https://doi.org/10.1007/s11936-002-0039-8
Behr ER, McKenna WJ. Hypertrophic Cardiomyopathy. Curr Treat Options Cardiovasc Med. 2002 Dec;4(6):443-453. doi: 10.1007/s11936-002-0039-8. PMID: 12408787.
Copy Download .nbib Format: NLM
Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation.

Environmental toxicology and pharmacology

Aupetit JF, Freysz M, Faucon G, Loufoua J, Timour Q.
PMID: 21781694
Environ Toxicol Pharmacol. 1996 Aug 15;2(1):1-7. doi: 10.1016/1382-6689(96)00027-0.

The effects of three quinidine-like drugs, disopyramide, lidocaine and flecainide were investigated in anaesthetized, open-chest pigs on vulnerability to ventricular fibrillation under normal conditions and under myocardial ischaemia conditions. Vulnerability to fibrillation was evaluated by electrical ventricular fibrillation threshold...

Cite
Aupetit JF, Freysz M, Faucon G, et al. Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation. Environ Toxicol Pharmacol. 1996;2(1):1-7doi: 10.1016/1382-6689(96)00027-0.
Aupetit, J. F., Freysz, M., Faucon, G., Loufoua, J., & Timour, Q. (1996). Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation. Environmental toxicology and pharmacology, 2(1), 1-7. https://doi.org/10.1016/1382-6689(96)00027-0
Aupetit, J F, et al. "Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation." Environmental toxicology and pharmacology vol. 2,1 (1996): 1-7. doi: https://doi.org/10.1016/1382-6689(96)00027-0
Aupetit JF, Freysz M, Faucon G, Loufoua J, Timour Q. Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation. Environ Toxicol Pharmacol. 1996 Aug 15;2(1):1-7. doi: 10.1016/1382-6689(96)00027-0. PMID: 21781694.
Copy Download .nbib Format: NLM
Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.

Therapeutic advances in infectious disease

Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A.
PMID: 25165548
Ther Adv Infect Dis. 2013 Aug;1(4):121-38. doi: 10.1177/2049936113497203.

BACKGROUND: The manufacturers of clarithromycin sought a drug similar in efficacy to erythromycin but with a superior side-effect profile. They generally achieved this outcome, but postmarketing findings identified a series of reports linking clarithromycin to QTc interval prolongation and...

Cite
Vieweg WV, Hancox JC, Hasnain M, et al. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis. 2013;1(4):121-38doi: 10.1177/2049936113497203.
Vieweg, W. V., Hancox, J. C., Hasnain, M., Koneru, J. N., Gysel, M., & Baranchuk, A. (2013). Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Therapeutic advances in infectious disease, 1(4), 121-38. https://doi.org/10.1177/2049936113497203
Vieweg, W Victor R, et al. "Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports." Therapeutic advances in infectious disease vol. 1,4 (2013): 121-38. doi: https://doi.org/10.1177/2049936113497203
Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis. 2013 Aug;1(4):121-38. doi: 10.1177/2049936113497203. PMID: 25165548; PMCID: PMC4040724.
Copy Download .nbib Format: NLM
Severe Hypoglycemia-induced Right Hemiparesis with Reversible Diffusion Restriction in the Left Internal Capsule Due to Combination Therapy Using Disopyramide and Clarithromycin.

NMC case report journal

Sugita Y, Koyanagi M, Oda M, Kobayashi T, Narumi O, Saiki M.
PMID: 29354336
NMC Case Rep J. 2017 Nov 21;5(1):31-33. doi: 10.2176/nmccrj.cr.2017-0045. eCollection 2018 Jan.

Severe hypoglycemia is known to cause acute focal neurological symptoms. In cases with a medical history of diabetes mellitus (DM), the diagnosis and treatment of hypoglycemia-induced neurological symptoms are simple. However, severe hypoglycemia can occur in patients who are...

Cite
Sugita Y, Koyanagi M, Oda M, et al. Severe Hypoglycemia-induced Right Hemiparesis with Reversible Diffusion Restriction in the Left Internal Capsule Due to Combination Therapy Using Disopyramide and Clarithromycin. NMC Case Rep J. 2017;5(1):31-33doi: 10.2176/nmccrj.cr.2017-0045.
Sugita, Y., Koyanagi, M., Oda, M., Kobayashi, T., Narumi, O., & Saiki, M. (2018). Severe Hypoglycemia-induced Right Hemiparesis with Reversible Diffusion Restriction in the Left Internal Capsule Due to Combination Therapy Using Disopyramide and Clarithromycin. NMC case report journal, 5(1), 31-33. https://doi.org/10.2176/nmccrj.cr.2017-0045
Sugita, Yoshito, et al. "Severe Hypoglycemia-induced Right Hemiparesis with Reversible Diffusion Restriction in the Left Internal Capsule Due to Combination Therapy Using Disopyramide and Clarithromycin." NMC case report journal vol. 5,1 (2018): 31-33. doi: https://doi.org/10.2176/nmccrj.cr.2017-0045
Sugita Y, Koyanagi M, Oda M, Kobayashi T, Narumi O, Saiki M. Severe Hypoglycemia-induced Right Hemiparesis with Reversible Diffusion Restriction in the Left Internal Capsule Due to Combination Therapy Using Disopyramide and Clarithromycin. NMC Case Rep J. 2017 Nov 21;5(1):31-33. doi: 10.2176/nmccrj.cr.2017-0045. eCollection 2018 Jan. PMID: 29354336; PMCID: PMC5767484.
Copy Download .nbib Format: NLM
Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil.

Journal of cardiology cases

Moriyama S, Yokoyama T, Irie K, Ito M, Tsuchihashi K, Fukata M, Kusaba H, Maruyama T, Akashi K.
PMID: 31719941
J Cardiol Cases. 2019 Aug 23;20(5):183-186. doi: 10.1016/j.jccase.2019.08.005. eCollection 2019 Nov.

Fluorouracil (5-FU), a commonly used anticancer agent, has potent cardiotoxicity that is mediated by vascular endothelial injury and vasospasm. Here, we report a patient demonstrating atrial fibrillation (AF), which was most likely induced by vasospasm mediated by 5-FU. A...

Cite
Moriyama S, Yokoyama T, Irie K, et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019;20(5):183-186doi: 10.1016/j.jccase.2019.08.005.
Moriyama, S., Yokoyama, T., Irie, K., Ito, M., Tsuchihashi, K., Fukata, M., Kusaba, H., Maruyama, T., & Akashi, K. (2019). Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. Journal of cardiology cases, 20(5), 183-186. https://doi.org/10.1016/j.jccase.2019.08.005
Moriyama, Shohei, et al. "Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil." Journal of cardiology cases vol. 20,5 (2019): 183-186. doi: https://doi.org/10.1016/j.jccase.2019.08.005
Moriyama S, Yokoyama T, Irie K, Ito M, Tsuchihashi K, Fukata M, Kusaba H, Maruyama T, Akashi K. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019 Aug 23;20(5):183-186. doi: 10.1016/j.jccase.2019.08.005. eCollection 2019 Nov. PMID: 31719941; PMCID: PMC6834961.
Copy Download .nbib Format: NLM
Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals.

American journal of therapeutics

Edeki T, Dillon-Moore B, He N.
PMID: 11862300
Am J Ther. 1996 Sep;3(9):611-615. doi: 10.1097/00045391-199609000-00002.

Interethnic difference in drug disposition is an important contributing factor to interindividual variation in drug response. Since interethnic differences in the protein binding of drugs may contribute to variation in drug disposition between ethnic groups, we conducted a study...

Cite
Edeki T, Dillon-Moore B, He N. Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals. Am J Ther. 1996;3(9):611-615doi: 10.1097/00045391-199609000-00002.
Edeki, T., Dillon-Moore, B., & He, N. (1996). Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals. American journal of therapeutics, 3(9), 611-615. https://doi.org/10.1097/00045391-199609000-00002
Edeki, Timi, et al. "Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals." American journal of therapeutics vol. 3,9 (1996): 611-615. doi: https://doi.org/10.1097/00045391-199609000-00002
Edeki T, Dillon-Moore B, He N. Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals. Am J Ther. 1996 Sep;3(9):611-615. doi: 10.1097/00045391-199609000-00002. PMID: 11862300.
Copy Download .nbib Format: NLM
Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Advances in medicine

Faber L.
PMID: 26556411
Adv Med. 2014;2014:464851. doi: 10.1155/2014/464851. Epub 2014 May 06.

Hypertrophic cardiomyopathy (HCM) is one of the more common hereditary cardiac conditions. According to presence or absence of outflow obstruction at rest or with provocation, a more common (about 60-70%) obstructive type of the disease (HOCM) has to be...

Cite
Faber L. Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care. Adv Med. 2014;2014:464851doi: 10.1155/2014/464851.
Faber, L. (2014). Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care. Advances in medicine, 2014464851. https://doi.org/10.1155/2014/464851
Faber, Lothar. "Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care." Advances in medicine vol. 2014 (2014): 464851. doi: https://doi.org/10.1155/2014/464851
Faber L. Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care. Adv Med. 2014;2014:464851. doi: 10.1155/2014/464851. Epub 2014 May 06. PMID: 26556411; PMCID: PMC4590958.
Copy Download .nbib Format: NLM
Pharmacologic Therapy of Hypertrophic Cardiomyopathy.

Current cardiology reviews

Sherrid MV.
PMID: 26333949
Curr Cardiol Rev. 2015 Sep 03; Epub 2015 Sep 03.

HCM is the most common inherited heart condition occurring in 1:500 individuals in the general population. Left ventricular outflow obstruction at rest or after provocation occurs in 2/3 of HCM patients and is a frequent cause of limiting symptoms....

Cite
Sherrid MV. Pharmacologic Therapy of Hypertrophic Cardiomyopathy. Curr Cardiol Rev. 2015;
Sherrid, M. V. (2015). Pharmacologic Therapy of Hypertrophic Cardiomyopathy. Current cardiology reviews, .
Sherrid, Mark V. "Pharmacologic Therapy of Hypertrophic Cardiomyopathy." Current cardiology reviews vol. (2015).
Sherrid MV. Pharmacologic Therapy of Hypertrophic Cardiomyopathy. Curr Cardiol Rev. 2015 Sep 03; Epub 2015 Sep 03. PMID: 26333949.
Copy Download .nbib Format: NLM
Ventricular tachycardia with congenital left ventricular aneurysm in an adult.

Interactive cardiovascular and thoracic surgery

Yamashiro S, Kuniyoshi Y, Miyagi K, Koja K.
PMID: 17669994
Interact Cardiovasc Thorac Surg. 2003 Mar;2(1):77-9. doi: 10.1016/S1569-9293(02)00103-2.

A 60-year-old woman without any risk factors for coronary artery disease presented with symptomatic, recurrent, non-sustained ventricular tachycardia. She was found to have a postero-lateral left ventricular aneurysm. Coronary angiography revealed normal coronary arteries. The 12-lead electrocardiogram showed sinus...

Cite
Yamashiro S, Kuniyoshi Y, Miyagi K, et al. Ventricular tachycardia with congenital left ventricular aneurysm in an adult. Interact Cardiovasc Thorac Surg. 2003;2(1):77-9doi: 10.1016/S1569-9293(02)00103-2.
Yamashiro, S., Kuniyoshi, Y., Miyagi, K., & Koja, K. (2003). Ventricular tachycardia with congenital left ventricular aneurysm in an adult. Interactive cardiovascular and thoracic surgery, 2(1), 77-9. https://doi.org/10.1016/S1569-9293(02)00103-2
Yamashiro, Satoshi, et al. "Ventricular tachycardia with congenital left ventricular aneurysm in an adult." Interactive cardiovascular and thoracic surgery vol. 2,1 (2003): 77-9. doi: https://doi.org/10.1016/S1569-9293(02)00103-2
Yamashiro S, Kuniyoshi Y, Miyagi K, Koja K. Ventricular tachycardia with congenital left ventricular aneurysm in an adult. Interact Cardiovasc Thorac Surg. 2003 Mar;2(1):77-9. doi: 10.1016/S1569-9293(02)00103-2. PMID: 17669994.
Copy Download .nbib Format: NLM
Interactions of rosiglitazone and anti-arrhythmic drugs in animal model.

Annals of medical and health sciences research

Mohammed Y, Mohammed E, Mohiuddin N, Syeda S.
PMID: 23440669
Ann Med Health Sci Res. 2012 Jul;2(2):152-6. doi: 10.4103/2141-9248.105663.

BACKGROUND: Diabetes increases the risk of vascular problems by two times compared with a healthy individual, with deposition of fats in blood vessel and this includes cardiovascular disease. The treatment regimens for patients suffering from both diseases generally include...

Cite
Mohammed Y, Mohammed E, Mohiuddin N, et al. Interactions of rosiglitazone and anti-arrhythmic drugs in animal model. Ann Med Health Sci Res. 2012;2(2):152-6doi: 10.4103/2141-9248.105663.
Mohammed, Y., Mohammed, E., Mohiuddin, N., & Syeda, S. (2012). Interactions of rosiglitazone and anti-arrhythmic drugs in animal model. Annals of medical and health sciences research, 2(2), 152-6. https://doi.org/10.4103/2141-9248.105663
Mohammed, Ym, et al. "Interactions of rosiglitazone and anti-arrhythmic drugs in animal model." Annals of medical and health sciences research vol. 2,2 (2012): 152-6. doi: https://doi.org/10.4103/2141-9248.105663
Mohammed Y, Mohammed E, Mohiuddin N, Syeda S. Interactions of rosiglitazone and anti-arrhythmic drugs in animal model. Ann Med Health Sci Res. 2012 Jul;2(2):152-6. doi: 10.4103/2141-9248.105663. PMID: 23440669; PMCID: PMC3573510.
Copy Download .nbib Format: NLM
Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins.

Bioinformation

Meraj K, Mahto MK, Christina NB, Desai N, Shahbazi S, Bhaskar M.
PMID: 23275710
Bioinformation. 2012;8(23):1139-46. doi: 10.6026/97320630081139. Epub 2012 Nov 23.

The sodium "channelopathies" are the first among the ion channel diseases identified and have attracted widespread clinical and scientific interests. Human voltage gated sodium channels are sites of action of several antiarrhythmic drugs, local anesthetics and related antiepileptic drugs....

Cite
Meraj K, Mahto MK, Christina NB, et al. Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins. Bioinformation. 2012;8(23):1139-46doi: 10.6026/97320630081139.
Meraj, K., Mahto, M. K., Christina, N. B., Desai, N., Shahbazi, S., & Bhaskar, M. (2012). Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins. Bioinformation, 8(23), 1139-46. https://doi.org/10.6026/97320630081139
Meraj, Khunza, et al. "Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins." Bioinformation vol. 8,23 (2012): 1139-46. doi: https://doi.org/10.6026/97320630081139
Meraj K, Mahto MK, Christina NB, Desai N, Shahbazi S, Bhaskar M. Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins. Bioinformation. 2012;8(23):1139-46. doi: 10.6026/97320630081139. Epub 2012 Nov 23. PMID: 23275710; PMCID: PMC3530882.
Copy Download .nbib Format: NLM
Showing 13 to 23 of 23 entries